>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

PI +18.1%, CYH +9.5%, TXN +8.7%, NOW +8% (also announces various collaborations), HZO +7.2%, FARO +7%, HAS +6.6%, OII +5.1%, STM +5.1%, VC +5%, RMD +4.9%, AMBP +4.7%, PEN +4%, EEFT +4%, NVCR +3.8%, EW +3.2%, LRCX +3.2%, WHR +2.9%, ALLE +2.8%, EPRT +2.7%, NEM +2.7%, CMS +2.7%, TECK +2.6%, HELE +2.6%, KDP +2.3%, TXT +2.3%, FAF +2.2%, WST +2.2%, BANC +2% (also increases share repurchase authorization to $300 mln), GGG +2%, URI +2% (also authorizes new $1.5 bln share repurchase program), LKQ +1.9%, FTI +1.9%, MBLY +1.9%, PTEN +1.7%, E +1.7%, FCFS +1.6%, CBRE +1.5%, HLX +1.4%, TPH +1.4%, RES +1.4%, BMY +1.3%, TYL +1.1%, AMED +1.1%, STRA +1.1%, ADT +1%, NDAQ +1%

Other news:

CADL +5.9% (announces oral presentation of Phase 3 CAN-2409 results)
AAPG +5.5% (To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin)
VSTM +2% (FDA clears Investigational NDA of VS-7375)
CRVS +2% (to present data from Phase 1 trial of Soquelitinib)
NG +1.7% (files mixed shelf securities offering)
HOMB +1.7% (increases dividend)
RES +1.4% (files $300 mln mixed shelf offering; also files for offering by selling shareholders)
KGS +1.3% (raises dividend by 10%)
IPHA +1.2% (announces €15 mln investment by Sanofi)

Analyst comments: